Infectious Diseases (ID) Fellowship Training is a 2-3 year program depending on the track the fellow chooses. The fellowship tracks are designed to meet all ACGME training requirements and 12 months of clinical experience and 24 months of continuity clinic experience for ABIM subspecialty board eligibility...


Suppose you lived in the mid-1800s in Cleveland, population 17,000. You likely wouldn't have ventured beyond the surrounding countryside, perhaps 10 to 20 miles at most, during your lifetime. Fast-forward to Cleveland today, population about 400,000. Air travel makes it possible to...

International Doctors

The international competition for postgraduate positions at University Hospitals Case Medical Center each year is a testament to the stature of our academic medical center among high-potential young physicians. This is especially true of more than 200 prestigious UH Case Medical Centerfellowships, which are globally recognized for preparing future leaders in medicine.

frame image
frame image

Welcome from the Division Chief

Welcome to the website for the Division of Infectious Diseases & HIV Medicine at Case Western Reserve University. We are incredibly proud of our tradition and accomplishments in contributing to the advancement of treatment of infectious diseases locally, nationally and worldwide.

Our core mission is to heal, to teach and to discover. Facing the challenges of emerging and re-emerging infectious diseases at home and across the globe; we pride ourselves on delivering the highest quality of care for our patients, providing exceptional fellowship training to the next generation of Infectious Diseases physicians and continuing to make scientific breakthroughs through our world renowned research.

STERIS Grant 2014 RFA

STERIS GrantThe Division of Infectious Diseases & HIV Medicine at Case Western Reserve University and University Hospitals Case Medical Center, with funds from STERIS Corporation, will provide seed money to faculty to foster research in emerging and healthcare-associated infections. Investigators in the basic science and clinical departments in the School of Medicine and Hospital System as well as in other departments throughout the University are eligible. Grants, not to exceed $37,500 direct costs each, will be awarded to investigators who intend to gather preliminary data to be used in seeking future independently funded awards. Basic science applications are encouraged but should have a clear translational component related to the themes of this request for application. Up to four grants annually will be awarded. At least one of these awards will be targeted directly to STERIS’ interests. The University Hospitals Research Institute will serve as the fiscal entity through which the monies will be distributed and awards administered.

Click here to get the RFA.

Research Support from the IDII

STERIS GrantThe Infectious Diseases & Immunology Institute (IDII) at Case Western Reserve University will provide seed money to young faculty to foster interdisciplinary research in infectious diseases and immunology. Investigators in the basic science and clinical departments in the School of Medicine and Hospital System as well as in other departments throughout the University are eligible. Grants, not to exceed $10,000 direct costs each, will be awarded to young investigators who intend to gather preliminary data to be used in seeking future independently funded awards. Research activity and themes should be multidisciplinary and involve investigators across the IDII. In the first year of funding, up to four grants will be awarded.

Click here to get the RFA.

Highly virulent, drug-resistant P. aeruginosa strain identified in Ohio

August 2014 – Researchers have identified a highly virulent, multidrug-resistant form of Pseudomonas aeruginosa in patient samples in a health care system in Ohio, according to a report in Antimicrobial Agents and Chemotherapy.

The pathogen produced metallo-beta-lactamase (MBL), which has remained uncommon in the United States, but is an emerging problem in P. aeruginosa in many other countries.

“Currently, [metallo-beta-lactamase]-mediated carbapenem resistance is infrequent in the United States, although national surveillance programs have detected blaMBLs in P. aeruginosa and other bacteria,” the researchers wrote. “At the local and regional level, the early detection of MBL-producing bacteria by clinical microbiology laboratories and their molecular characterization can help inform efforts to prevent and control their dissemination.”

The initial isolate was identified in March 2012 in a patient in a long-term care facility. The patient was a 69-year-old man with type 2 diabetes and the pathogen was found in a foot wound. Six additional patients were affected across three community hospitals, one long-term care facility and one tertiary care center, and one patient died.

The P. aeruginosa pathogen produced the Verona integron-encoded MBL (VIM-2) and was resistant to all fluoroquinolones, aminoglycosides and beta-lactams. Two of the isolates were also non-susceptible to colistin, the typical “agent of last resort.”

In addition, the researchers found that the integron was part of a region that included a transposon and the Salmonella genomic island 2, which indicated a recombination event between Salmonella and P. aeruginosa, adding even more resistance genes.

“This is the first description of genetic exchange of a large mobile element — the Salmonella genome island — and resistance genes between P. aeruginosa and Salmonella,” Federico Perez, MD, of the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, said in a press release. “This movement of genetic material creates concern that metallo beta-lactamases will disseminate rapidly in these enteric pathogens that are also very invasive. We are also concerned about the possibility of enhanced virulence.”

Read the article.

CWRU wins $12.7 million for AIDS research, clinical trials

AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

This award includes $12.7 million for core research funding and the potential of an additional $9 million to support clinical trials of promising treatments. This award marks the fifth time the Case Western Reserve University (CWRU)/University Hospitals (UH) AIDS Clinical Trials Unit has received NIAID funding since it began operating in 1987.

"We are very proud to have received this competitive award," said co-principal investigator Michael Lederman, the Scott R. Inkley Professor of Medicine and associate director of the Center for AIDS Research at Case Western Reserve School of Medicine and infectious disease specialist at UH Case Medical Center. "It shows a level of confidence in our unit that encourages and inspires us." Read more...

Robert Salata


  • The ID Alliance, led by Dr. Amanda Healan and Dr. Robert Salata, has successfully earned funding from the United Black Fund of Greater Cleveland ($5,000) and The Cleveland Foundation ($25,000) to sustain its Peer Educator program. The program teaches high school students about sexually transmitted infections (STIs) and effective prevention strategies. Peer Educators are empowered to facilitate educational workshops for other youth groups. Funding will be utilized for Peer Educator stipends and to support open Peer Educator training sessions twice monthly at J. Glen Smith Health Center. The training sessions are part of Teen Night Tuesdays at the health center, which the ID Alliance co-sponsors. For more information, visit www.IDAlliance.org or contact IDAlliance@case.edu.
  • Case Western Reserve University recently became a site institution for the the Sexually Transmitted Infections Clinical Trials Group (STI CTG) with Robert A. Salata, M.D. as the PI. There were only 3 awards nationally for funding over 7 years. The STI-CTG is a collaboration of institutions that work together to identify, support, and administer clinical trials that will contribute to the reproductive health of people and specifically lead to prevention and control of sexually transmitted infections (STIs). This award is through the National Institutes of Health and the National Institute for Allergy and Infectious Diseases administered through the Division of Microbiology and Infectious Diseases (DMID).
  • Drs. Jump (Robin Jump, MD, PhD), Olds and Higgins, together with their colleagues Dr. Ken Schaemder from the VA in Durham, NC and Dr. Chris Crnich from the VA in Madison, WI, were awarded $247,000 from the VA Geriatric Research Education and Clinical Center (GRECC). Their proposal, "A Multi-Site Educational Intervention to Improve the Treatment of Infections Among Older Veterans," will implement two educational tracks, one for prescribers and one for nursing staff, across several VA facilities. Their long-term goal is to improve antimicrobial utilization for older adults.
  • Robert A. Salata, MD, Chief of the Division of Infectious Diseases and HIV Medicine, and Medical Director, Infection Control and Prevention at UH Case Medical Center, is principal investigator of a study to evaluate the safety, tolerability and appropriate dosing for aerosol and intravenous versions of an antibiotic called colistin. This drug was introduced in the 1960s, and was never subjected to the testing that modern regulatory review requires. Therefore, the best and safest ways to use it against most infections are largely unknown. The National Institutes of Health funded the study through a one-of-a-kind contract with Case Western Reserve University School of Medicine specifically awarded for phase 1 clinical trials in infectious disease.
  • Dr. Usha Stiefel's independent proposal entitled "Role of Microbial Eradication in Preventing Recurrent MRSA Infection" was selected for a 2012 ASPIRE Award. The ASPIRE Awards in Antibacterial Research are competitive, externally reviewed grant awards sponsored by Pfizer, Inc. The project will evaluate the hypothesis that antimicrobials displaying superior rates of microbial eradication and superior rates of intestinal pathogen eradication will be associated with decreased rates of recurrent infection with methicillin-resistant Staphylococcus aureus (MRSA) in veteran patients.